Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features

Introduction: Vitiligo is thought to be an autoimmune disorder caused by melanocytes dysfunction and depigmentation. Among different executors of the immune system in developing the disease, the role of various cytokines has been defined. Objectives: We have focused on IL-38, the tenth member of...

Full description

Bibliographic Details
Main Authors: Maryam Zarrabi, Nasser Gholijani, Zahra Amirghofran, Maryam Sadat Sadati, Roya Radanfar
Format: Article
Language:English
Published: Mattioli1885 2024-01-01
Series:Dermatology Practical & Conceptual
Subjects:
Online Access:https://dpcj.org/index.php/dpc/article/view/3520
_version_ 1797324046260502528
author Maryam Zarrabi
Nasser Gholijani
Zahra Amirghofran
Maryam Sadat Sadati
Roya Radanfar
author_facet Maryam Zarrabi
Nasser Gholijani
Zahra Amirghofran
Maryam Sadat Sadati
Roya Radanfar
author_sort Maryam Zarrabi
collection DOAJ
description Introduction: Vitiligo is thought to be an autoimmune disorder caused by melanocytes dysfunction and depigmentation. Among different executors of the immune system in developing the disease, the role of various cytokines has been defined. Objectives: We have focused on IL-38, the tenth member of IL-1 cytokine family with a proposed anti-inflammatory role, which has not hitherto been introduced as an anti-inflammatory factor in vitiligo. Methods: Sixty-nine generalized vitiligo patients and 72-year-old- and sex-matched healthy individuals were included in this study. IL-38 level was evaluated in sera of all participants using ELISA assay. The relation of IL-38 level to patients characteristics was evaluated. Results: IL-38 serum level in vitiligo patients (159.5±39.7 pg/ml) was lower than the healthy controls (166.7±34.8pg/ml) (P = 0.039). A weak negative correlation between the age of male patients and their IL-38 serum levels was identified (r = 0.38, P = 0.058). Evaluation of the IL-38 serum levels relationship with patients clinical characteristics showed no correlation with disease onset, stage of depigmentation, and disease activity status. Conclusions: The lower levels of IL-38 as an anti-inflammatory cytokine support the inflammatory nature of vitiligo. It indicates the difference of IL-38 in sera of vitiligo patients and healthy controls, as the first report of the lower level of this cytokine in the context of vitiligo. The reason of this difference remains to be clarified; as there are not sufficient study reports revealing the role of gender, ethnicity and inflammation on the cytokine network in the context of vitiligo.
first_indexed 2024-03-08T05:44:36Z
format Article
id doaj.art-3e43dedd825e44eb8b1e3e99f0c6260c
institution Directory Open Access Journal
issn 2160-9381
language English
last_indexed 2024-03-08T05:44:36Z
publishDate 2024-01-01
publisher Mattioli1885
record_format Article
series Dermatology Practical & Conceptual
spelling doaj.art-3e43dedd825e44eb8b1e3e99f0c6260c2024-02-05T13:15:33ZengMattioli1885Dermatology Practical & Conceptual2160-93812024-01-0114110.5826/dpc.1401a27Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features Maryam Zarrabi0Nasser Gholijani1Zahra Amirghofran2Maryam Sadat Sadati3Roya Radanfar4Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, IranAutoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, IranAutoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran ,Immunology Department, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Dermatology, Shiraz University of Medical Sciences, Shiraz, IranDepartment of dermatology, Shiraz University of Medical Sciences, Shiraz, Iran Introduction: Vitiligo is thought to be an autoimmune disorder caused by melanocytes dysfunction and depigmentation. Among different executors of the immune system in developing the disease, the role of various cytokines has been defined. Objectives: We have focused on IL-38, the tenth member of IL-1 cytokine family with a proposed anti-inflammatory role, which has not hitherto been introduced as an anti-inflammatory factor in vitiligo. Methods: Sixty-nine generalized vitiligo patients and 72-year-old- and sex-matched healthy individuals were included in this study. IL-38 level was evaluated in sera of all participants using ELISA assay. The relation of IL-38 level to patients characteristics was evaluated. Results: IL-38 serum level in vitiligo patients (159.5±39.7 pg/ml) was lower than the healthy controls (166.7±34.8pg/ml) (P = 0.039). A weak negative correlation between the age of male patients and their IL-38 serum levels was identified (r = 0.38, P = 0.058). Evaluation of the IL-38 serum levels relationship with patients clinical characteristics showed no correlation with disease onset, stage of depigmentation, and disease activity status. Conclusions: The lower levels of IL-38 as an anti-inflammatory cytokine support the inflammatory nature of vitiligo. It indicates the difference of IL-38 in sera of vitiligo patients and healthy controls, as the first report of the lower level of this cytokine in the context of vitiligo. The reason of this difference remains to be clarified; as there are not sufficient study reports revealing the role of gender, ethnicity and inflammation on the cytokine network in the context of vitiligo. https://dpcj.org/index.php/dpc/article/view/3520vitiligointerleukin38cytokineskin
spellingShingle Maryam Zarrabi
Nasser Gholijani
Zahra Amirghofran
Maryam Sadat Sadati
Roya Radanfar
Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features
Dermatology Practical & Conceptual
vitiligo
interleukin38
cytokine
skin
title Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features
title_full Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features
title_fullStr Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features
title_full_unstemmed Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features
title_short Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features
title_sort evaluation of il 38 a newly introduced cytokine in sera of vitiligo patients and its relation to clinical features
topic vitiligo
interleukin38
cytokine
skin
url https://dpcj.org/index.php/dpc/article/view/3520
work_keys_str_mv AT maryamzarrabi evaluationofil38anewlyintroducedcytokineinseraofvitiligopatientsanditsrelationtoclinicalfeatures
AT nassergholijani evaluationofil38anewlyintroducedcytokineinseraofvitiligopatientsanditsrelationtoclinicalfeatures
AT zahraamirghofran evaluationofil38anewlyintroducedcytokineinseraofvitiligopatientsanditsrelationtoclinicalfeatures
AT maryamsadatsadati evaluationofil38anewlyintroducedcytokineinseraofvitiligopatientsanditsrelationtoclinicalfeatures
AT royaradanfar evaluationofil38anewlyintroducedcytokineinseraofvitiligopatientsanditsrelationtoclinicalfeatures